FindTrial
Sign In

Real-world efficacy and safety of nab-paclitaxel based chemotherapy with or without immune checkpoint inhibitors as second-line therapy in patients with advanced biliary tract cancers: a retrospective analysis

Real-world efficacy and safety of nab-paclitaxel based chemotherapy with or without immune checkpoint inhibitors as second-line therapy in patients with advanced biliary tract cancers: a retrospective analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096599
Enrollment
Unknown
Registered
2025-01-26
Start date
2025-01-27
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced biliary tract cancers

Interventions

Observation group:None
Control group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with biliary tract cancer receiving a second-line nab-paclitaxel-containing regimen

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Overall survival time;—

Secondary

MeasureTime frame
Objective response rate;Progression free survival time;—

Countries

China

Contacts

Public ContactYang Yu

West China Hospital of Sichuan University

yangyuflying@hotmail.com+86 136 6627 7535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026